Latest Breaking News On - Full data readout expected - Page 1 : comparemela.com

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomMarshallh woodworthMichael millerNeurobo pharmaceuticals incRx communications groupPrnewswire neurobo pharmaceuticals incDonga st coNeurobo pharmaceuticalsFull data readout expectedSecond halfG protein coupled receptorHyung heon kimChief executive officerMetabolic dysfunction associated steatohepatitisPrivate securities litigation reform act

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomMarshallh woodworthMichael millerPrnewswire neurobo pharmaceuticals incDrug administrationNeurobo pharmaceuticals incDonga st coRx communications groupNeurobo pharmaceuticalsFull data readout expectedSecond halfG protein coupled receptorHyung heon kimChief executive officerMetabolic dysfunction associated steatohepatitisPrivate securities litigation reform act

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

United statesPaula schwartzAndreas muehlerJessica breuDaniel vittEdna kaplanExchange commissionRx communications groupImmunic inc nasdaqImmunic incUnblinded interim biomarker analysis expectedFull data readout expectedChief executive officerChief medical officerNorth americaEastern europe

EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P.

United statesJessica breuDaniel vittEdna kaplanPaula schwartzAndreas muehlerExchange commissionImmunic incDistribution servicesRx communications groupCompletes enrollmentIts phaseVidofludimus calciumProgressive multiple sclerosisProgressive multipleUnblinded interim biomarker analysis expected